Invitrogen™ Felvizumab Humanized Recombinant Human Monoclonal Antibody

Catalog No.	Quantity
PIMA541723	100 μg

Catalog No. PIMA541723 Supplier Invitrogen™ Supplier No. MA541723

Description

Human Recombinant Monoclonal Antibody

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Felvizumab is a biosimilar that targets RSV. Human respiratory syncytial virus (RSV) is a member of the Paramyxoviridae family, subfamily Pneumovirinae, that causes common respiratory tract infections such as measles and mumps. Its genome consists of single stranded, negative sense RNA that encodes three envelope glycoproteins, a small hydrophobic (SH) protein of unknown function, a major glycoprotein (G) known as the attachment protein, and a fusion (F) protein. Its name comes from the fact that F proteins on the surface of the virus cause the membranes on nearby cells to merge, forming syncytia. While RSV typically produces mild symptoms in adults, it is one of the leading causes of lower respiratory tract infections and hospital visits during infancy and childhood.

Specifications

• Antigen: Felvizumab Humanized
• Applications: ELISA, SDS-Page
• Classification: Recombinant Monoclonal
• Concentration: 2.54 mg/mL
• Conjugate: Unconjugated
• Formulation: PBS with no preservative; pH 7.5
• Gene Alias: SB 209763
• Host Species: Human
• Immunogen: Respiratory syncytial virus- RSV.
• Purification Method: Protein A
• Quantity: 100 μg
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Target Species: Virus
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Product Type: Antibody
• Form: Liquid
• Isotype: IgG1 κ
• Target Molecule: Chemical

Safety and Handling

WARNING: Cancer - www.P65Warnings.ca.gov